Introduction {#section6-0269881119855978}
============

Sleep disturbances are highly prevalent in the general population. Consensus has been reached that around 30% of the adult population reports some form of sleep complaint ([@bibr2-0269881119855978]; [@bibr27-0269881119855978]) whereas approximately 6--8% meets the diagnostic criteria for clinical insomnia ([@bibr32-0269881119855978]; [@bibr45-0269881119855978]). This is of high clinical relevance as inadequate sleep contributes to a diversity of medical conditions ([@bibr9-0269881119855978]; [@bibr33-0269881119855978]; [@bibr42-0269881119855978]) and is one of the primary risk factors for major depression ([@bibr3-0269881119855978]). These findings emphasize the need to identify factors involved in the aetiology of sleep disturbances and develop adequate clinical interventions.

Genetic factors considerably contribute to the aetiology of sleep disturbances as demonstrated in heritability ([@bibr5-0269881119855978]; [@bibr6-0269881119855978]; [@bibr11-0269881119855978]; [@bibr28-0269881119855978]; [@bibr50-0269881119855978]) and genome-wide association studies ([@bibr19-0269881119855978]; [@bibr23-0269881119855978]; [@bibr26-0269881119855978]). As a specific candidate gene, accumulating evidence suggests that a functional polymorphism (serotonin transporter gene-linked polymorphic region; 5-HTTLPR) within the promoter region of the serotonin (5-hydroxytriptamine; 5-HT) transporter gene (SLC6A4) modulates the risk for sleep impairment. This polymorphism regulates the transcriptional efficiency of the 5-HT transporter via an allelic variation: the short (S) allele is associated with reduced expression and functioning of the 5-HT transporter relative to the long (L) allele ([@bibr21-0269881119855978]), although complex mechanisms may mediate a more diverse influence on 5-HT neurotransmission ([@bibr30-0269881119855978]). As a consequence of this deficient 5-HT functioning, the 5-HTTLPR S-allele is found to predispose to risk of stress-related ([@bibr8-0269881119855978]; [@bibr22-0269881119855978]) and depression-related ([@bibr35-0269881119855978]) sleep disturbance as well as clinical insomnia ([@bibr12-0269881119855978]; [@bibr22-0269881119855978]), even though these findings have not always been consistently replicated ([@bibr4-0269881119855978]; [@bibr48-0269881119855978], [@bibr49-0269881119855978]). In line with the involvement of 5-HT in sleep regulation ([@bibr47-0269881119855978]), these findings suggest that genetic influences on 5-HT neurotransmission considerably contribute to the aetiology of sleep impairment.

The observation that the 5-HTTLPR S-allele promotes sleep disturbance encourages the search for pharmacological interventions aimed to compensate for deficient 5-HT functioning. Brain 5-HT is synthesized in serotonergic neurons from the essential amino acid tryptophan, where it is first metabolized into the immediate 5-HT precursor 5-hydroxytryptophan (5-HTP) by the enzyme tryptophan hydroxylase. Since this enzyme is not fully saturated, it provides a rate-limiting step that controls further 5-HT synthesis depending on tryptophan availability ([@bibr15-0269881119855978]; [@bibr52-0269881119855978]). In this context, the synthetic pathway of 5-HT is very sensitive to pharmacological increments in tryptophan availability, which are found to rapidly increase brain 5-HT levels ([@bibr13-0269881119855978]; [@bibr14-0269881119855978]) even at low pharmaceutical dosage ([@bibr16-0269881119855978]). Specific effects of tryptophan on sleep regulation have been repeatedly demonstrated in both healthy subjects and those with insomnia including a reduced sleep onset latency, increased total sleep time and decreased wake after sleep onset (for review, see [@bibr20-0269881119855978]; [@bibr41-0269881119855978]; [@bibr43-0269881119855978]). Taken together, these findings indicate that tryptophan augmentation holds promise as a pathway to compensate for the 5-HT-related sleep disturbances associated with the 5-HTTLPR S-allele. Although one previous investigation supports particular sleep-promoting effects in this allelic variant ([@bibr48-0269881119855978]), studies including evening tryptophan administration, more detailed sleep assessment and within-subjects comparisons are desirable to further establish this pharmacogenetic effect.

The present study investigated whether subchronic pre-sleep tryptophan administration improves sleep depending on allelic variation in 5-HTTLPR. In a double-blind placebo-controlled crossover design a well-screened sample of homozygous S-allele and L-allele carriers were monitored for subjective (sleep diary) and objective (actigraphy) sleep during a treatment protocol consisting of 1 week of pre-sleep placebo (1000 mg/day) and 1 week of pre-sleep tryptophan administration (1000 mg/day). It is expected that tryptophan improves objectively and subjectively measured sleep, particularly in the low-expressive 5-HTTLPR S-allele.

Methods {#section7-0269881119855978}
=======

Participants {#section8-0269881119855978}
------------

Participants were obtained from a recently created 5-HTTLPR database (*n* = 804) and were carefully selected based on the following inclusion and exclusion criteria. Inclusion criteria encompassed: homozygous S'/S' (S/S, S/L~g~, L~g~/L~g~) or L'/L' (L~a~/L~a~) 5-HTTLPR genotype. Exclusion criteria comprised: diabetes, pregnancy or breast feeding, bladder problems (physical irritation, bladder cancer), gastrointestinal diagnosis (diminished amount of gastric acid, diminished absorption in the upper bowel), psychiatric diagnosis, sleep disorder diagnosis, heavy snoring and shift work (contemporary or during the past month) as well as the use of sleep medication, antidepressants, antipsychotics or recreational drugs (during or within 1 month prior to study participation). The final sample (*n* = 98), consisting of S'/S' (*n* = 47) and L'/L' (*n* = 51) 5-HTTLPR genotypes, included 25 (25.5%) male and 73 (74.5%) female participants aged between 20 and 30 years of age (*M* = 22.21, SD = 2.00). The procedures followed were approved by the local ethics committee of Maastricht University (Ethical Review Committee Psychology and Neuroscience; ERCPN) and are in line with the guidelines laid down in the Declaration of Helsinki 1975, revised in 2013 ([@bibr51-0269881119855978]). Written informed consent was obtained from all subjects, and participants received financial compensation for their contribution to the study.

Genotyping {#section9-0269881119855978}
----------

Sterile swabs (Omni Swabs; Whatman, Maidstone, United Kingdom) were used to acquire buccal cell samples for 5-HTTLPR determination. Isolation of genomic DNA was performed using QIamp DNA Mini Kits (Qiagen, Leusden, The Netherlands). Polymerase chain reaction protocol was followed for the subsequent 5-HTTLPR genotyping ([@bibr18-0269881119855978]). More recent findings revealed that fragments in the 5-HTTLPR L-allele affect the transcription of the 5-HT transporter including a high-expressive L~a~ and a low-expressive L~g~ variant ([@bibr31-0269881119855978]). Consistent with previous research ([@bibr54-0269881119855978]), tri-allelic variants were therefore reclassified into a functionally relevant bi-allelic model including S'/S' (S/S, S/L~g~, L~g~/L~g~), S'/L' (S/L~a~, L~g~/L~a~) and L'/L' (L~a~/L~a~) respectively. Hardy--Weinberg equilibrium (HWE) was determined for the initial database and revealed that genotype frequencies of S'/S' (*n* = 190), S'/L' (*n* = 405) and L'/L' (*n* = 209) did not differ from HWE (χ^2^ = 0.052, *p* = 0.820).

Procedure {#section10-0269881119855978}
---------

The influence of tryptophan on objective and subjective sleep was assessed using a double-blind placebo-controlled crossover design. Homozygous S-allele and L-allele carriers completed a within-subjects treatment protocol consisting of 1 week of placebo and 1 week of tryptophan administration (1000 mg/day; administered 20 minutes before bedtime). Treatment order was randomized across participants and counterbalanced within 5-HTTLPR genotype groups. Sleep assessment comprised a daily sleep diary and actigraphy measurements during the night. Prior to the start of the study, participants completed general questionnaires and received verbal instructions regarding the treatment administration, sleep diary and actigraphy device. Participants were further asked to attain similar bedtimes and rising times throughout the experimental period.

Treatment {#section11-0269881119855978}
---------

During the treatment protocol, participants self-administered two capsules every evening exactly 20 minutes prior to bedtime (i.e. lights out). Depending on the treatment week, capsules either contained tryptophan (500 mg per capsule, 1000 mg in total) or placebo (microcrystalline cellulose) but were identical in appearance. This administration interval allows for a substantial amount of tryptophan uptake as peak plasma levels are generally obtained in 1 to 2 hours after administration ([@bibr53-0269881119855978]). In order to assess treatment compliance participants were asked to write down the exact time of administration or indicate that they did not administer the respective capsules.

Sleep diary {#section12-0269881119855978}
-----------

The morning diary of the consensus sleep diary (CSD) was used for subjective sleep assessment ([@bibr10-0269881119855978]). This daily questionnaire has been developed by leading sleep experts and provides a standardized sleep diary to improve the comparability of sleep studies ([@bibr10-0269881119855978]). Apart from general bedtimes and rising times, this sleep diary included subjective reports of sleep onset latency, amount of nocturnal awakenings, wake after sleep onset, sleep quality (ranging from 1 very poor to 5 very good) and refreshed sleep (ranging from 1 not rested at all to 5 very well rested). Recent comparisons between insomnia patients and healthy controls support the validity and clinical utility of the CSD ([@bibr29-0269881119855978]).

Actigraphy {#section13-0269881119855978}
----------

Activity-based sleep--wake monitoring (i.e. actigraphy) was used for objective sleep assessment. Methodological research indicates that actigraphy is a valid and reliable method for objective sleep assessment that is particularly sensitive to detecting sleep alterations related to pharmacological interventions (for review, see [@bibr39-0269881119855978]). Sleep data were recorded using the GT3X+ activity monitor (ActiGraph, Pensacola, Florida, USA). This device includes a tri-axial solid-state accelerometer to measure activity. The actigraph was worn on the wrist of the non-dominant hand according to common conventions. Data were recorded at a sampling rate of 30 Hz with a low- and high-pass frequency filter of 2.5 Hz and 0.25 Hz respectively. Recorded sleep data were processed using ActiLife software (ActiLife 6.0, ActiGraph, Pensacola, Florida, USA).

Bedtimes and rising times reported in the sleep diary were entered to indicate the sleep period for each respective night. Data for each night were visually inspected to determine whether the actigraph was worn during the night and corresponded with reported sleep times. Sleep--wake scoring of the data was performed in 1-minute epochs using a commonly used algorithm validated for the age of the present sample ([@bibr40-0269881119855978]). The scored data were subsequently used to calculate the sleep parameters of interest including sleep onset latency, sleep efficiency, time in bed, wake after sleep onset, nocturnal awakenings and average awakening length. Polysomnographic comparisons revealed that a GT3X+ actigraphy device combined with the algorithm used in the present study produces a sensitivity, specificity and accuracy of 90%, 46% and 84% respectively ([@bibr44-0269881119855978]).

Missing data {#section14-0269881119855978}
------------

Data concerning the sleep diary and actigraphy variables were indicated as missing for a respective night if treatment compliance could not be ensured (placebo: *M* = 0.22, SD *=* 0.83; tryptophan: *M* = 0.22, S*D* = 0.78), either because the time of capsule administration was missing or the participant reported that the treatment was not administered. Data on actigraphy variables were further excluded for a respective night if the device was either not worn (placebo: *M* = 0.34, *SD =* 0.61; tryptophan: *M* = 0.31, SD = 0.58) or became detached during the night (placebo: *M* =0.03, SD *=* 0.17; tryptophan: *M* = 0.01, SD = 0.10), the sleep period could not be determined because the sleep diary bedtime or rising time was missing (placebo: *M* = 0.35, SD *=* 0.92; tryptophan: *M* = 0.34, SD = 0.93) or when the reported sleep period time was not corresponding with actigraphy data based on visual inspection (placebo: *M* = 0.59, SD *=* 1.02; tryptophan: *M* = 0.53, SD = 0.84). On average 12.64 (*SD* = 2.78) and 11.43 (*SD* = 2.94) of the 14 nights were included per participant for the sleep diary (placebo: *M* = 6.30, SD *=* 1.53; tryptophan: *M* = 6.35, SD = 1.43) and actigraphy data (placebo: *M* = 5.63, SD *=* 1.74; tryptophan: *M* = 5.80, SD = 1.49) respectively. This indicates that compliance in the present study was generally high.

Statistical analyses {#section15-0269881119855978}
--------------------

Statistical analyses were conducted in SPSS (SPSS 24.0 statistics for Windows, IBM, Armonk, New York). Linear mixed model analyses including a random intercept (indicating repeated measurements for each participant) were performed to investigate whether the influence of treatment (tryptophan versus placebo) on subjective (sleep diary) and objective (actigraphy) sleep parameters varied as a function of 5-HTTLPR (S'/S' versus L'/L'). Sleep variables of interest were retrieved from the subjective sleep diary reports (i.e. sleep onset latency, nocturnal awakenings, wake after sleep onset, total sleep time, sleep quality, refreshed sleep) and objective actigraphy recordings (i.e. sleep onset latency, sleep efficiency, total sleep time, wake after sleep onset, nocturnal awakenings). General influences of treatment were first explored in a linear mixed model that included treatment as a single predictor for sleep variables. The differential influence of treatment depending on 5-HTTLPR was subsequently investigated in a linear mixed model that included treatment, 5-HTTLPR and an interaction term of the two predictors. Simple main effects of treatment within 5-HTTLPR genotype groups and of 5-HTTLPR within treatment conditions were used to interpret significant interactions.

Results {#section16-0269881119855978}
=======

Sample characteristics {#section17-0269881119855978}
----------------------

[Table 1](#table1-0269881119855978){ref-type="table"} presents the sample characteristics in relation to allelic variation in 5-HTTLPR. As demonstrated, no significant mean differences were observed between the two genotype groups regarding relevant variables.

###### 

Sample characteristics *M* (SD).

![](10.1177_0269881119855978-table1)

           S'/S'          L'/L'          *t*-test   
  -------- -------------- -------------- ---------- -------
  *n*      47             51                        
   Men     11             14                        
   Women   36             37                        
  Age      22.53 (2.12)   21.92 (1.86)   1.514      0.133
  PSQI     4.47 (1.97)    4.10 (2.42)    0.820      0.414
  ISI      5.04 (3.05)    4.55 (3.88)    0.703      0.484
  CES-D    7.43 (7.39)    7.00 (7.00)    0.291      0.771

CES-D: Center for Epidemiological Studies Depression Scale; ISI: Insomnia Severity Index; *M*: mean; *n*: number of participants; *p: p*-value; PSQI: Pittsburgh Sleep Quality Index; SD: standard deviation; *t*: t-statistic.

Subjective sleep {#section18-0269881119855978}
----------------

Linear mixed model analyses including treatment (tryptophan versus placebo) as a single predictor revealed no significant main effects on any of the subjective sleep variables ([Table 2](#table2-0269881119855978){ref-type="table"}).

###### 

Estimated marginal means *M* (SE) of sleep variables within treatment conditions.

![](10.1177_0269881119855978-table2)

                                  Placebo                                                                                                                    Tryptophan                                                                                                                                                                                                                     
  ------------------------------- -------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------- --------------------------------------------------------------------- -------------------------------------------------------------------- -------------- ---------------------------------------------------------------------
  *Sleep diary*                                                                                                                                                                                                                                                                                                                                                                             
   Sleep onset latency (min)      20.11 (2.53)                                                                                                               17.05 (2.46)                                                         18.53 (1.76)                                                          18.78 (2.53)                                                         15.48 (2.46)   17.08 (1.76)
   Nocturnal awakenings           1.61 (0.13)                                                                                                                1.36 (0.13)                                                          1.48 (0.09)                                                           1.49 (0.13)                                                          1.54 (0.13)    1.51 (0.09)
   Wake after sleep onset (min)   11.93 (1.69)                                                                                                               8.83 (1.63)                                                          10.33 (1.18)                                                          12.77 (1.69)                                                         10.44 (1.64)   11.57 (1.18)
   Total sleep time (h)           7.67 (0.11)                                                                                                                7.58 (0.10)                                                          7.62 (0.07)                                                           7.58 (0.11)                                                          7.66 (0.10)    7.62 (0.07)
   Sleep quality                  3.60 (0.07)^[a](#table-fn3-0269881119855978){ref-type="table-fn"},[b](#table-fn4-0269881119855978){ref-type="table-fn"}^   3.90 (0.07)^[b](#table-fn4-0269881119855978){ref-type="table-fn"}^   3.75 (0.05)                                                           3.71 (0.07)^[a](#table-fn3-0269881119855978){ref-type="table-fn"}^   3.81 (0.07)    3.76 (0.05)
   Refreshed sleep                3.26 (0.09)                                                                                                                3.43 (0.88)                                                          3.35 (0.06)                                                           3.28 (0.09)                                                          3.37 (0.88)    3.24 (0.06)
  *Actigraphy*                                                                                                                                                                                                                                                                                                                                                                              
   Sleep onset latency (min)      6.64 (0.72)                                                                                                                6.06 (0.70)                                                          6.34 (0.50)                                                           6.96 (0.71)                                                          6.03 (0.69)    6.48 (0.50)
   Sleep efficiency (%)           84.42 (0.75)                                                                                                               84.97 (0.73)                                                         84.70 (0.52)^[c](#table-fn5-0269881119855978){ref-type="table-fn"}^   85.26 (0.74)                                                         86.08 (0.73)   85.68 (0.52)^[c](#table-fn5-0269881119855978){ref-type="table-fn"}^
   Total sleep time (h)           6.78 (0.12)                                                                                                                6.71 (0.11)                                                          6.74 (0.08)                                                           6.76 (0.12)                                                          6.86 (0.11)    6.81 (0.08)
   Wake after sleep onset (min)   68.06 (3.60)                                                                                                               65.53 (3.50)                                                         66.76 (2.50)^[c](#table-fn5-0269881119855978){ref-type="table-fn"}^   63.13 (3.57)                                                         60.09 (3.49)   61.57 (2.49)^[c](#table-fn5-0269881119855978){ref-type="table-fn"}^
   Nocturnal awakenings           24.34 (0.92)                                                                                                               23.54 (0.89)                                                         23.93 (0.64)                                                          23.69 (0.91)                                                         23.37 (0.89)   23.52 (0.64)

*M*: mean; *SE*: standard error.

Main effect of treatment in S'/S' group (*p* \< 0.10).

Main effect of 5-HTTLPR in placebo condition (*p* \< 0.01).

Main effect of treatment (*p* \< 0.001).

As illustrated in [Figure 1](#fig1-0269881119855978){ref-type="fig"}, linear mixed model analyses including treatment (tryptophan versus placebo), 5-HTTLPR (S'/S' versus L'/L') and an interaction term as predictors for subjective sleep variables revealed a significant interaction between treatment and 5-HTTLPR on subjective sleep quality (*b* = 0.200, *t*(1208.72) = 2.490, *p* = 0.013) and subjective amount of nocturnal awakenings (*b* = −0.296, *t*(1216.69) = −2.045, *p* = 0.041). Simple main effects of treatment within 5-HTTLPR genotype groups revealed a marginally significant improvement of subjective sleep quality in the S'/S' (*b* = 0.111, *t*(1208.23) = 1.929, *p* = 0.054) but not in the L'/L' group (*b* = −0.89, *t*(1209.24) = −1.587, *p* = 0.113) following tryptophan compared to placebo intake. Moreover, a significantly poorer sleep quality in the S'/S' as opposed to the L'/L' group in the placebo condition (*b* = −0.300, *t*(133.92) = −2.985, *p* = 0.003) was not observed in the tryptophan condition (*b* = −0.099, *t*(133.65) = −0.990, *p* = 0.324). Simple effects within 5-HTTLPR and treatment groups did not reveal further significant main effects except for a marginally significant increase in the number of nocturnal awakenings in the L'/L' group following tryptophan relative to placebo intake (*b* = 0.175, *t*(1216,80) = 1.740, *p* = 0.082). No significant interactions were observed for the remainder of subjective sleep variables ([Table 2](#table2-0269881119855978){ref-type="table"}).

![Interaction between 5-HTTLPR and treatment for (a) subjective sleep quality (*p* \< 0.05) and (b) subjective number of nocturnal awakenings (*p* \< 0.05).](10.1177_0269881119855978-fig1){#fig1-0269881119855978}

Objective sleep {#section19-0269881119855978}
---------------

Linear mixed model analyses with treatment (tryptophan versus placebo) as a single predictor for objective sleep variables revealed a significant increase in sleep efficiency (*b* = 0.977, *t*(1027.10) = 3.337, *p* \< 0.001) and a reduction in objective wake after sleep onset (*b* = −5.188, *t*(1027.83) = −3.502, *p* \< 0.001) following tryptophan relative to placebo intake ([Figure 2](#fig2-0269881119855978){ref-type="fig"}). No significant main effects of treatment were observed for the remainder of the objective sleep variables ([Table 2](#table2-0269881119855978){ref-type="table"}).

![Main effect of treatment on (a) objective sleep efficiency (*p* \< 0.001) and (b) objective wake after sleep onset (*p* \< 0.001).](10.1177_0269881119855978-fig2){#fig2-0269881119855978}

Linear mixed model analyses with treatment (tryptophan versus placebo, 5-HTTLPR (S'/S' versus L'/L') and an interaction term as predictors for objective sleep variables revealed no significant interactions ([Table 2](#table2-0269881119855978){ref-type="table"}). This indicates that 5-HTTLPR does not moderate the effect of tryptophan on objectively measured sleep.

Discussion {#section20-0269881119855978}
==========

The results of the present study support the sleep-promoting effects of tryptophan and indicate that some influences depend on allelic variation in 5-HTTLPR. While tryptophan improved objective sleep efficiency and objective wake after sleep onset irrespective of allelic variation, 5-HTTLPR was found to moderate the influence of tryptophan on subjective sleep quality and subjective number of nocturnal awakenings, as measured by the respective items of the sleep diary. A marginally significant improvement of sleep quality in the S-allele but not in the L-allele group illustrates the value of tryptophan as a compensatory treatment for the presumed elevated susceptibility for sleep impairment in this allelic variant. This is further supported by the observation that a significantly lower subjective sleep quality in the S-allele relative to the L-allele in the placebo condition diminished following tryptophan treatment.

The significantly lower sleep quality in the 5-HTTLPR S-allele during placebo administration corresponds with previous work revealing an increased susceptibility for sleep quality reductions ([@bibr8-0269881119855978]) and clinical insomnia ([@bibr12-0269881119855978]; [@bibr22-0269881119855978]) in this allelic variant. While 5-HTTLPR-dependent differences were observed for subjective sleep quality, no genetic influences were found for objective measurements. A low correspondence between subjective sleep quality and actigraphy has been commonly reported ([@bibr39-0269881119855978]), and it has been suggested that the two assessment methods capture different sleep dimensions ([@bibr1-0269881119855978]). This parallels the discrepancy in subjective and objective sleep commonly observed in clinical insomnia ([@bibr37-0269881119855978]). The distinction between subjective sleep perception and objective sleep measures might be particularly relevant to the field of 5-HTTLPR as previous research mainly included subjective sleep reports ([@bibr4-0269881119855978]; [@bibr8-0269881119855978]; [@bibr22-0269881119855978]; [@bibr35-0269881119855978]; [@bibr48-0269881119855978], [@bibr49-0269881119855978]). Hence, this could suggest that 5-HTTLPR particularly modulates subjective aspects of sleep. Nonetheless, given the enduring validity issues with actigraphy ([@bibr39-0269881119855978]), and in the absence of polysomnographic studies, it cannot be excluded that objective sleep alterations account for 5-HTTLPR-dependent differences in subjective sleep quality.

The present study revealed that tryptophan improves subjective sleep quality in S-allele but not in L-allele carriers. This finding is in accordance with previous work demonstrating that tryptophan administration is associated with significantly better sleep quality in stress vulnerable individuals carrying two copies of the S-allele ([@bibr48-0269881119855978]). However, in the present study the effect of tryptophan in the S-allele group was relatively small and only approached statistical significance. Although this may intrinsically relate to the effect of tryptophan, it is likely that this at least in part reflects a ceiling effect related to the high sleep quality of the studied sample. Hence, this profoundly limits the room for improvement on the already restricted response options of the subjective sleep quality item. Subjective results further revealed a marginally significant increase in the reported number of nocturnal awakenings in the L-allele group. Taken together, the direction of 5-HTTLPR-dependent treatment effects provides some indications that tryptophan may improve subjective sleep in the S-allele group, whereas it might impair subjective sleep in the L-allele group.

In line with a large body of research supporting the sleep-promoting effects of tryptophan ([@bibr20-0269881119855978]; [@bibr41-0269881119855978]; [@bibr43-0269881119855978]), actigraphic findings revealed that tryptophan improves sleep efficiency and reduces wake after sleep onset irrespective of allelic 5-HTTLPR variation. Comparing these objective effects with the influence of tryptophan on subjective measures, there appears to be a marked difference among sleep assessment procedures. Hence, while tryptophan improved objective sleep irrespective of allelic variation, it exclusively increased subjective sleep quality in S-allele relative to L-allele carriers. This might suggest that tryptophan specifically improves subjective sleep perception in the 5-HTTLPR S-allele, whereas it does not result in an actual improvement in objectively measured sleep. This could result from a reduction in the negative attentional bias associated with this allelic variant ([@bibr34-0269881119855978]) and, hence, the involvement of the serotonergic system in the inhibition of such maladaptive cognitive processes ([@bibr38-0269881119855978]). Alternatively, tryptophan might selectively improve sleep architecture in the 5-HTTLPR S-allele resulting in an objective sleep improvement that cannot be detected by actigraphic measures.

The precise mechanism underlying the general sleep-promoting effects of tryptophan remains largely unknown; however, there is specific evidence that the biosynthetic pathway of 5-HT is involved in sleep regulation. This is mainly derived from animal research revealing that pharmacological blocking of the enzyme tryptophan hydroxylase with para-chlorophenylalanine (pCPA) results in profound sleep impairments ([@bibr7-0269881119855978]; [@bibr24-0269881119855978]; [@bibr25-0269881119855978]; [@bibr46-0269881119855978]) that can be reversed by 5-HTP ([@bibr25-0269881119855978]; [@bibr36-0269881119855978]) and tryptophan ([@bibr7-0269881119855978]) administration. Since this rate-limiting enzyme is also thought to mediate the effects of tryptophan on 5-HT synthesis, these findings provide indirect support for the sleep-promoting effects of tryptophan augmentation. It remains uncertain, however, how general increments in brain 5-HT synthesis exert sleep-inducing effects. This relates to the complex involvement of 5-HT in sleep--wake regulation, as its activity promotes both sleep and wakefulness depending on current behavioural state, brain region and 5-HT receptor type as well as its interrelationships with other neurotransmitter and hormonal systems (for review, see [@bibr47-0269881119855978]).

The diminished expression of the 5-HT transporter in the 5-HTTLPR S-allele produces a variety of neurochemical changes in the brain 5-HT system. Expanding on the influence of tryptophan on 5-HT-mediated sleep regulation, such alterations might explain why sleep-improving effects may particularly occur in this allelic variant. As comprehensively reviewed ([@bibr30-0269881119855978]), research in humans and mice with comparable levels of 5-HT transporter expression as homozygous S-allele carriers (i.e. SLC6A4^+/--^) indicates that a diminished transcriptional activity of the 5-HT transporter decreases the amount of 5-HT transporter binding sites. This reduces 5-HT reuptake resulting in elevated extracellular 5-HT concentrations and prolonged 5-HT clearance. This augmented 5-HT signalling is accompanied by a reduced basal 5-HT firing rate in the dorsal raphe as well as a downregulation of 5-HT~1A~, 5-HT~1B~ and 5-HT~3~ receptors. Since the 5-HT~1A~ receptor is thought to facilitate sleep (for review, see [@bibr47-0269881119855978]), a decreased sensitivity might theoretically contribute to the sleep quality reductions associated with the 5-HTTLPR S-allele. Research in mice lacking 5-HT transporter expression (i.e. SLC6A4^−/--^) further suggests that 5-HT synthesis and turnover might increase to compensate for the reduced recycling of 5-HT (for review, see [@bibr30-0269881119855978]). Since an elevation in tryptophan availability increases 5-HT synthesis and release ([@bibr15-0269881119855978]; [@bibr52-0269881119855978]), such mechanisms provide a potential pathway as to how tryptophan might compensate for the deficient 5-HT functioning and related sleep disturbances in the 5-HTTLPR S-allele. Regardless of the precise molecular mechanism of action, research on a variety of outcome measures supports the assumption that the 5-HTTLPR S-allele is generally more susceptible to manipulations of tryptophan availability (for review, see [@bibr17-0269881119855978]).

The following limitations should be considered for the present study. The first limitation relates to the relatively high sleep quality of the present sample. This is an important issue as this may considerably reduce potential treatment effects, and future research in clinical populations is therefore encouraged. The second limitation pertains to the objective sleep assessment. Although 1 week of actigraphy sleep assessment is found to provide a reliable estimate of sleep parameters ([@bibr1-0269881119855978]) the accuracy of detecting nocturnal awakenings during sleep periods (i.e. specificity) is relatively limited, and polysomnographic studies are needed to detect more valid objective influences. Further research involving different doses of tryptophan is also desirable, as higher doses of tryptophan administration might produce more profound effects on sleep regulation.

In conclusion, current findings support the sleep-promoting effects of tryptophan augmentation. The present study elaborates on more general findings revealing that tryptophan may particularly improve subjective sleep quality in genetic variants associated with deficient 5-HT functioning. Given the involvement of the 5-HTTLPR S-allele in the aetiology of reduction in sleep quality and clinical insomnia, tryptophan supplementation holds promise as a valuable treatment strategy to compensate for this predisposition, although research in clinical populations is desirable.
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